C-Bridge Capital, a US$700 million-under-management healthcare private equity fund in China, has led a US$100 million new funding round in Chinese pharmaceutical start-up Ascletis, according to Chinese media reports.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?